Drugs / GSK598809
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT00728897 | Jul 2008 | substance dependence | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00728052 | Jun → Aug 2008 | substance dependence | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00605241 | Feb 2008 → Mar 2009 | substance dependence | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00468806 | Apr 2007 → May 2008 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00437840 | Mar → Jun 2007 | substance dependence | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00437632 | Mar 2007 → Aug 2008 | substance dependence | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01188967 | Aug 2010 → May 2013 | nicotine dependence | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00793468 | Dec 2008 | nicotine dependence | GlaxoSmithKline | Withdrawn | No outcome recorded Stop: Enrollment |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT00908206 Comparator | May → Jul 2009 | alcohol dependence | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 1 | NCT01039454 Comparator | Dec 2008 → Apr 2010 | substance dependence | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00887367 Comparator | Sep → Dec 2008 | substance dependence | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK598809 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01039454 ↗ |
| Action | Inhibit | “oral administration of various doses of the selective D(3) receptor antagonist, GSK598809” PMID 20599188 ↗ Aug 2010 |
| Route | Oral | “Subjects will receive GSK598809 capsules orally with water.” NCT00437632 ↗ |
| Target | DRD3 | “a selective DRD3 Antagonist” NCT00605241 ↗ |